A panelist discusses how interpreting clinical trial data, monitoring disease progression, and maintaining transparent communication help retina specialists make informed decisions about when and how ...

The investigators noted that this report is the first about subretinal drusenoid deposits in Black and Hispanic patients with age-related macular degeneration. Researchers from the New York Eye and ...

Ashkan Abbey, MD, FASRS, FAAO, from Texas Retina Associates discussed EYP-1901, an innovative intravitreal insert that releases vorolanib, a potent tyrosine kinase inhibitor designed to treat retinal ...

This year, 18 presenters will deliver named lectures during the American Academy of Ophthalmology meeting. Lee M. Jampol, MD, will deliver the lecture “How to Describe New Diseases, the Same Skills ...

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and ...

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources. Kristina Pfau, MD, FEBO, is a ...

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. It was also approved by the European ...